<DOC>
	<DOCNO>NCT01472653</DOCNO>
	<brief_summary>The therapy patient locally advanced head neck cancer adjust grade skin rush record first two cycle Cetuximab Cisplatin , i.e . either radioimmunotherapy ( radiotherapy Cetuximab ) radiochemotherapy ( radiotherapy Cisplatin .</brief_summary>
	<brief_title>Treatment Selection According Skin Reaction Cetuximab</brief_title>
	<detailed_description>Background : According literature , treatment result irradiate patient develop intensive skin reaction concomitant Cetuximab administration appear improve compare result standard combination radiotherapy Cisplatin . In patient , beneficial effect Cetuximab expect therapy Cisplatin ( concomitantly irradiation ) effective group . In proposed single-institution non-randomized phase II study patient locally advance squamous cell carcinoma head neck , therapy adjust grade skin rush record first two cycle Cetuximab Cisplatin , i.e . either radioimmunotherapy ( radiotherapy Cetuximab ) radiochemotherapy ( radiotherapy Cisplatin ) . Methods : In patient inoperable tumor , induction chemotherapy ( Docetaxel 75 mg/m2 , Cisplatin 75 mg/m2 , 5-Fluorouracil 750 mg/m2 continuous infusion day 1-5 ; repeat every 21 day 4 cycle ) administer . In week first fraction radiotherapy , patient receive load dose Cetuximab ( 400 mg/m2 ) combination Cetuximab ( 250 mg/m2 ) Cisplatin ( 30 mg/m2 ) first week irradiation . After multidisciplinary assessment grade skin rush , conduct end second week irradiation , patient group follow : arm A - skin rush CTCAE v3.0 grade &lt; 2 proceed radiochemotherapy Cisplatin ; arm B - skin rush CTCAE v3.0 grade &gt; =2 proceed radioimmunotherapy Cetuximab . The planned number patient include study 120 ( arm A - 50 , arm B - 70 ) recruitment period 3 year . The primary objective study determine radiologically complete response rate 12-14 week therapy . The secondary objective locoregional control , progression-free survival overall survival 2 year therapy , acute late toxicity . Expected result : The expected complete response rate patient treat radiochemotherapy treat radioimmunotherapy 50 % 75 % , respectively . We also expect difference absolute survival gain group 25 % .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Squamous cell carcinoma , histologically prove ( HPVstatus determine patient oropharyngeal primary ) Tumour site : oral cavity , oropharynx , hypopharynx larynx . Locally and/or regionally operable inoperable tumor ( UICC TNM stag III , IVa IVb ) , without distant metastasis ( M0stage ) Male female ≥18 year age Expected survival &gt; 6 month WHO performance status 02 Laboratory parameter : hemoglobin ≥100 g/L ; leukocyte count &gt; 3.5x109/L , absolute neutrophil count ≥ 1.5x109/L ; platelet count &gt; 100x109/L ; total bilirubin &lt; 1.25x upper normal limit ; transaminase ( ALT , AST ) &lt; 5x upper normal limit ; creatinine clearance ( ECC ) ≥ 60 ml/minute ; Presence least one bidimensionally measurable index lesion Effective contraception male female subject risk conception exists Signed write informed consent Other previous malignancy within 5 year , exception history previously adequately treat basal cell carcinoma skin pre invasive carcinoma cervix Chemotherapy ineligibility : unstable cardiopulmonary , renal liver disease likely compromise safe delivery I.V . infusion ( chemotherapy ) ; haematologic disease ; clinically evident hearing impairment ; preexist motor sensory neurotoxicity grade ≥ 2 accord CTCAE v3.0 ; previous administration Cetuximab Cisplatin ; Active , uncontrolled infection Medical psychological condition opinion investigator precludes safe administration plan radiotherapy systemic therapy Known drug abuse severe alcohol abuse Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Head neck Cancer</keyword>
	<keyword>Radiochemotherapy</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Skin rush</keyword>
	<keyword>locoregional control</keyword>
	<keyword>Survival</keyword>
	<keyword>Toxicity</keyword>
</DOC>